primarily necessitating high dosages (radioactivities to be administered) for tumor control. The injected activity was adapted, if necessary, on the basis of not only the patient’s clinical condition, hematologic results, a...
We propose that the assay presented here could guide preclinical investigations of FAP biology and the clinical development of FAP inhibitors or FAP-localized anti-tumor therapies in the future. As a complement to the in vitro assay, we are also investigating the potential utility of aP NIRF ...
Panbela Therapeutics president and CEO Dr Jennifer Simpson said: “Our focus on disruptive therapeutics for urgent unmet medical needs is at the core of what we do at Panbela. “We believe that Flynpovi has the potential to make a meaningful difference for patients with FAP, and we are com...